We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Epimed Lands Form 483 for Inadequate Procedures

Epimed Lands Form 483 for Inadequate Procedures

April 28, 2017

Epimed International Inc. was cited in a Form 483 for inadequate procedures for handling of complaints, design validation, design transfer, control over products, services and suppliers, and accepting incoming products at its Johnstown, N.Y. facility.

The FDA cited the manufacturer of pain management, radio frequency and cryoanalgesia products for five observations.

The inspector’s first observation found that the company failed to adequately establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit.

The 483 also cites Epimed for not adequately establishing procedures for design validation and design transfer. For example, the validation of a catheter was approved without a missing data point regarding catheter removal being identified or corrected, and the design validation did not follow the firm’s procedures.

The inspector also found that the type and extent of control to be exercised over the firm’s products, services, and suppliers were not clearly defined.

Specifically, the supplier of Epimed’s bulk non-sterile RK epidural needles changed production to a new site and new contract manufacturer. However, Epimed had no documentation showing approval of this change and did not define the extent of control it had over the supplier.

Finally, the inspector found that the company had not established adequate procedures for accepting incoming products, including epidural needles.

An effective corrective and preventive action (CAPA) program is integral to a successful quality management system. Ten of the industry’s top experts, who have together managed thousands of root cause investigations and successfully opened and closed more CAPAs than they can remember, share everything from the nuts and bolts of CAPA management to the most innovative best practices. Creating QSR-Compliant CAPA Systems walks you through everything you need to know to plan, implement and manage an effective CAPA system.

View today's stories

Devices Quality

    Upcoming Events

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Survey Shows Nearly All Pharm Techs Face Drug Shortages, Pfizer Plant Shortages Continue Until 2024

    • FDA Shares Premarket Requirements for Device Cybersecurity in Final Guidance

    • Potential Penalties Force BMS to Sign Drug Price Negotiation Agreement With CMS

    • Despite AdComm Endorsement, neffy Nasal Spray Alternate for EpiPen Gets CRL

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing